42. Serum CYFRA 12-1 in Cervical Cancer Patients Treated with Radiation Therapy

Yoshiyuki Suzuki,M.D., Takashi Nakano,]VI.D Tatsuya Ohno,M.0., Atsuko Abe,M.0 Shinroku Morita,M.D., and Hirohiko Tsujii,M.D

Keywords: radiation therapy, cervical cancer

A fragment of cytokerratin 19, referred to as CYFRA 21-1 is abundant in serum of many patients with malignant tumors and it is recognized as a tumor marker, especially for non-small cell lung cancer. In this study, clinical usefulness of CYFRA 21 1 was investigated in cervical cancer patients treated with radiation therapy, with reference to squamous cell carcinoma related antigen (SCC-Ag) which is a common tumor marker for cervical squamous cell carctnoma.

The serum levels of CYFRA 21-1 and SCC-Ag were measured for 50 patients with squamous cell carcinoma of the uterine cervix before and after treatment their radiation treatment. The percentage of abnormal level of CYFRA 21-1 was 52 %. The incidenee increased with stage advancement. The rn crease in the level of the patients after treatment was a sign of the disease progression. During radiation, serum level of CYFRA 21-1 decreased significantly for patients who had obtained local control and the level reflected the radiation effect well.

Additionally, CYFRA 21-1 was negative in all patients without distant metastasis at the end of radiation therapy. Compared with SCC-Ag, the positivity of CYFRA 21-1 was statistically lower. As for a correlation between the levels of CYFRA 21-1 and SCC-Ag, there was a statistically positive correla tion (correlation tmatrix=O.69).

These results indicated that CYFRA 21-1 can play an important role in monitoring outcome of patients with squamous cell carcinoma of the uterine cervix. The usefulness may be significant for patients without SCC-Ag.